Potentiation of antibiotic activity by a novel cationic peptide: Potency and spectrum of activity of SPR741

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Corbett, David ^a   Wise, Andrew ^a   Langley, Tara ^a   Skinner, Kirsty ^a   Trimby, Emily ^a   Birchall, Stephen ^a   Dorali, Alain ^a   Sandiford, Stephanie ^a   Williams, Jennifer ^a   Warn, Peter ^a   Vaara, Martti ^b   Lister, Troy ^c  

^a EVOTEC UK LTD   (United Kingdom)

^b Technopolis   (Finland)

^c Drug Product Development   (United States)

Author keywords

Gram negative bacteria; Microbiology; Potentiation

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FIDAXOMICIN; FOSFOMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; MECILLINAM; MEROPENEM; NALIDIXIC ACID; NITROFURANTOIN; NOVOBIOCIN; POLYMYXIN B; PSEUDOMONIC ACID; RAMOPLANIN; RETAPAMULIN; RIFAMPICIN; SPR 741; TEICOPLANIN; TELITHROMYCIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE PERMEABILITY; DRUG SYNERGISM; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B;

EID: 85026367284     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00200-17     Document Type: Article

References (27)

1. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. 2016. Antimicrobial resistance. JAMA 316:1193–1204. https://doi.org/10.1001/jama.2016.11764.
2. Johnson AP, Woodford N. 2013. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase NDM-mediated carbapenem resistance. J Med Microbiol 62:499–513. https://doi.org/10.1099/jmm.0.052555-0.
3. Meletis G. 2016. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis 3:15–21. https://doi.org/10.1177/2049936115621709.
4. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601. https://doi.org/10.1016/S1473-3099(06)70580-1.
5. Yahav D, Farbman L, Leibovici L, Paul M. 2012. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 18:18 –29. https://doi.org/10.1111/j.1469-0691.2011.03734.x.
6. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40. https://doi.org/10.1038/nrd2201.
7. Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. Science 325:1089–1093. https://doi.org/10.1126/science.1176667.
8. Livermore DM. 2011. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 66:1941–1944. https://doi.org/10.1093/jac/dkr262.
9. Delcour AH. 2009. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 1794:808–816. https://doi.org/10.1016/j.bbapap.2008.11.005.
10. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol Rev 56:395–411.
11. Vaara M. 2013. Novel derivatives of polymyxins. J Antimicrob Chemother 68:1213–1219. https://doi.org/10.1093/jac/dkt039.
12. Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 54:3341–3346. https://doi.org/10.1128/AAC.01439-09.
13. Clinical and Laboratory Standards Institute. 2015. M100-S26. Performance standards for antimicrobial susceptibility testing, 26th ed. Approved standard. CLSI, Wayne, PA.
14. Felmingham D. 2001. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 7(Suppl 3):S2–S10. https://doi.org/10.1046/j.1469-0691.2001.0070s3002.x.
15. Felmingham D, Farrell DJ. 2006. In vitro activity of telithromycin against Gram-negative bacterial pathogens. J Infect 52:178–180. https://doi.org/10.1016/j.jinf.2005.05.014.
16. Jones RN, Fritsche TR, Sader HS, Ross JE. 2006. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 50:2583–2586. https://doi.org/10.1128/AAC.01432-05.
17. Biedenbach DJ, Rhomberg PR, Mendes RE, Jones RN. 2010. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). Diagn Microbiol Infect Dis 66:301–307. https://doi.org/10.1016/j.diagmicrobio.2009.10.014.
18. Piddock LJ. 2006. Multidrug-resistance efflux pumps — not just for resistance. Nat Rev Microbiol 4:629–636. https://doi.org/10.1038/nrmicro1464.
19. Chollet R, Chevalier J, Bryskier A, Pagès JM. 2004. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 48:3621–3624. https://doi.org/10.1128/AAC.48.9.3621-3624.2004.
20. Zgurskaya HI, Krishnamoorthy G, Ntreh A, Lu S. 2011. Mechanism and function of the outer membrane channel TolC in multidrug resistance and physiology of enterobacteria. Front Microbiol 2:189. https://doi.org/10.3389/fmicb.2011.00189.
21. Randall CP, Mariner KR, Chopra I, O’Neill AJ. 2013. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother 57:637–639. https://doi.org/10.1128/AAC.02005-12.
22. Paukner S, Wicha WW, Heilmayer W, Thirring K, Riedl R. 2015. Abstr 55th Intersci Conf Antimicrob Agents Chemother, abstr F-1185.
23. Schumacher A, Trittler R, Bohnert JA, Kümmerer K, Pagès JM, Kern WV. 2007. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother 59:1261–1264. https://doi.org/10.1093/jac/dkl380.
24. Clinical and Laboratory Standards Institute. 2015. M7-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 10th ed. Approved standard. CLSI, Wayne, PA.
25. Garcia L. 2010. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p 140–162. In Clinical Microbiology Procedures Handbook, 3rd ed. ASM Press, Washington, DC. https://doi.org/10.1128/9781555817435.ch5.12.
26. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11:427–433. https://doi.org/10.1093/jac/11.5.427.
27. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. https://doi.org/10.1093/jac/dkg301.